A Tiny Pill Could Turn the Tide Against Heart Disease

Last week the FDA gave the green light to enlicitide, a small tablet you pop each morning with a sip of coffee, water or tea. No fancy injections, no specialist appointments—just a pill that can lower low‑density lipoprotein (LDL), the “bad” cholesterol, by almost 60 %. That’s roughly the same drop you get from the strongest injectable drugs on the market today.

It may not sound as flashy as gene‑editing or AI‑driven therapies, but the story behind enlicitide is a reminder that medicine often wins by refining what we already know. The drug is the latest chapter in a decades‑long effort to tame heart disease, which still claims more lives in the United States than any other condition. In 2025 alone, 694,708 Americans died from cardiovascular problems—about one in five deaths, eclipsing even cancer.

Good news: the tide is turning. Since the 1950s, age‑adjusted deaths from heart disease in the U.S. have plummeted by roughly three‑quarters. A 60‑year‑old today faces a risk of dying from a heart attack that’s about a quarter of what it was when Harry Truman was president. That progress hinges largely on one number—LDL.

For most of us, high LDL was a stubborn, almost inevitable fact of life. Diet and exercise could nudge it down a bit, but the big reductions seemed out of reach. Then, about twenty years ago, two geneticists at the University of Texas Southwestern—Helen Hobbs and Jonathan Cohen—found a handful of people, many of them Black Americans, who carried a natural loss‑of‑function mutation in a gene called PCSK9. Their bodies cleared LDL with extraordinary efficiency, resulting in roughly 28 % lower cholesterol and an 88 % lower risk of heart disease.

That discovery proved lowering LDL could literally save lives and gave drug developers a clear target: mimic the PCSK9 mutation. The first wave of PCSK9‑inhibiting drugs were injectable monoclonal antibodies, effective but inconvenient for many patients. Enlicitide is the oral answer—delivering the same LDL‑slashing power without a needle and without the muscle aches that force many people off statins.

Statins are still the workhorse for cholesterol control, and they have saved countless lives. Yet a sizable chunk of patients can’t tolerate them, and even among those who can, some never achieve the LDL levels they need. Enlicitide aims to fill that gap, offering a pill that’s as potent as the injections but easier to stick with.

Looking even further ahead, researchers are tackling the adherence problem itself. Verve Therapeutics, now part of Eli Lilly, has been testing a one‑time gene‑editing therapy that permanently turns off the PCSK9 gene in the liver. In early human trials, a single infusion knocked LDL down by up to 62 % and kept it low for more than a year. If that approach pans out, patients might never have to remember a daily pill again.

Of course, cholesterol is only one piece of the cardiovascular puzzle. Smoking rates have collapsed from about 40 % of adults in the 1960s to under 15 % today, a change that alone saved millions of arteries. Blood‑pressure management has improved dramatically, with cheap generics catching problems early. And the newer class of GLP‑1 drugs—originally marketed for obesity—are also slashing heart‑related events; semaglutide, for example, reduced cardiovascular incidents by roughly 20 % in a major trial.

Still, the battle isn’t over. Enlicitide’s impressive lab results haven’t yet been tied to reduced mortality—long‑term outcome data won’t be ready for a few years. Moreover, while heart‑attack deaths have plunged, deaths from other cardiac conditions like heart failure and arrhythmias have risen sharply, reflecting a shifting disease landscape.

The bottom line is that progress against heart disease is a marathon, not a sprint. A pill like enlicitide is a valuable tool, but it only works if people actually take it. That’s why the promise of a one‑time gene edit feels so tantalizing: a solution that can’t be forgotten. Until then, the quiet, incremental advances—better pills, smarter public‑health policies, and wider access to care—continue to chip away at the world’s deadliest killer.